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Abstract
Cancer patients experience several stressors and emotional upheavals. Fear of death, interruption
of life plans, changes in body image and self-esteem, changes in social role and lifestyle are all
important issues to be faced. Moreover, Depressive Disorders may impact the course of the
disease and compliance. The cost and prevalence, the impairment caused, and the diagnostic and
therapeutic uncertainty surrounding depressive symptoms among cancer patients make these
conditions a priority for research. In this article we discuss recent data, focusing on detection of
Depressive Disorders, biological correlates, treatments and unmet needs of depressed cancer
patients.
1. Background
Cancer accounts for nearly 25% of deaths in the United
States, exceeded only by heart disease [1]. Major Depres-
sive Disorder accounts for 4.4 percent of the overall global
disease burden, a contribution similar to ischemic heart
disease or diarrhoeal disease [2], and the Disability
Adjusted Life Years (DALYs) for depression in the near
future will be greater than cancer or HIV related disease
[3]. A strong body of evidence demonstrates the coexist-
ence of depression and cancer, reported prevalence rates
of depression for solid tumours ranging from 20 to 50%.
These results generally include all the depressive disorders
not just the Major Depressive Disorder. Grassi and Rosti
found that out of 201 recently diagnosed cancer patients,
15% met the criteria for a Major Depressive Disorder [4].
Sharpe estimated at 8% the prevalence of Major Depres-
sive Disorder in a large sample of cancer patients,
although most of them had an inactive disease [5]. In a
sample of haematological inpatients prevalence of Major
Depression was 9% [6], the same reported by Coyne et al
among breast cancer patients [7]. In the screening pro-
gram conducted by Ell and colleagues among low-income
women with cancer the prevalence rate for Major Depres-
sion was 24% [8]. There is reason to believe that many
patients affected by subclinical depression go undetected.
These estimates are made around time of cancer diagno-
sis. More research is needed to establish the prevalence of
depressive disorders in the years after the diagnosis using
standardized diagnostic criteria. The prevalence of Major
Depressive Disorder at time of the first breast cancer recur-
rence was estimated at 22% by Okamura [9]. In a recent
observational cohort study, conducted among 222
women with a diagnosis of early breast cancer, prevalence
of depression and anxiety was 33% at diagnosis, 15% after
one year, and 45% after diagnosis of recurrence [10].
The reported variability in prevalence is attributable to
several factors: medical, personal and factors related to
different study methods, instruments and procedures. Not
all cancer patients are the same: cancer site, age, disease
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stage, time from diagnosis, cancer treatment, are among
the most important variables associated with prevalence
of depression among cancer patients and these should be
taken into account. Psychiatric morbidity and other psy-
chological aspects among breast cancer patients are very
well studied, while fewer reports regard cancer of other
sites. [6,11-13]. Personal variables such as cultural and
ethnical characteristics, religious attitudes, social eco-
nomic status, personality traits, coping styles, social sup-
port, distance from hospital are also very important. Not
all trials have taken into account the different stages of the
cancer process. The importance of these variables has
been recently confirmed by results obtained from an
observational study, conducted on 2.600 women treated
for early breast cancer, showing that depressive symptoms
were not associated with objective cancer-related factors
[14]. In the absence of sufficient formal trial data in cancer
patients, clinical decision should be influenced by experi-
ence in the general population, and naturalistic studies
appearing in cancer literature [15].
Over the last years many efforts have been made in order
to improve screening procedures, but at present no stand-
ardized approach exists for the diagnosis of depression
among cancer patients. An additional source of variation
is represented by the between observer variability; but,
perhaps, in practice, what really matters and makes the
difference is the professional background, with particular
reference to knowledge in psychopathology and clinical
experience. Inadequate diagnosis of Major Depression
among cancer patients causes reduction in quality of life,
prolonged hospitalization and higher rates of non com-
pliance with treatment plan [16]. In addition social sup-
port has been identified as an important factor alleviating
depression in cancer patients, consequently, family coun-
selling should be usefully employed to educate the family
on depression that accompanies cancer [17].
2. Assessment of depression among cancer 
patients
In the field of psycho-oncology the widely used instru-
ments BSI (Brief Symptoms Inventory) [18] and the
HADS (Hospital Anxiety and Depression Scale) [19] are
employed for detecting psychological distress. Such scales
were specifically developed to identify symptoms in non
psychiatric medical outpatients. These instruments con-
tributed to the recognition of psychological suffering in
different settings, and improved psycho-oncology. Never-
theless too often prevalence of psychiatric disorders is
reported only on the basis of studies using HADS and BSI.
In many studies the CES-D (Centre for Epidemiological
Studies-Depression) [20] or the BDI (Beck Depression
Inventory) [21], showing acceptable sensitivities and spe-
cificities in samples of cancer patients, were employed.
On the other hand, patients with symptoms of depression
may not fulfil the DSM-IV criteria for Depressive Disor-
ders [22]. This is a crucial point. As an example, the
reported high rate of Adjustment Disorders is due in part
to the special status of being a cancer patient, and in part
to the inadequacy of DSM-IV criteria for such patients, a
sort of makeshift solution.
Moreover the prevalence of depression among cancer
patients is often underestimated, because many symp-
toms of depression, such as fatigue, weight loss, loss of
appetite or sleep disruption, closely mirror the physio-
logic effects of cancer; or the use of certain treatments and
other symptom management medication may preclude
an appropriate diagnosis. [18]. As suggested by some
authors [23] it is necessary to adopt an adequate approach
for discriminating the somatic symptoms of cancer and
those due to treatment from the criteria of DSM-IV for
major depression. Three models were proposed: the inclu-
sive ones, which suggest that somatic symptoms are
counted regardless of the cause; the substituted ones,
which suggest that non somatic symptoms are substituted
for somatic symptoms; the exclusive ones, which suggest
that somatic symptoms may be disregarded as diagnostic
criteria [17]. As an example of the exclusive approach, it
has been proposed to remove fatigue from the DSM-IV cri-
teria. In our opinion the modified DSM-IV approach to
diagnose Major Depression proposed at the Memorial
Sloan-Kettering Cancer Centre, that eliminates anorexia
and fatigue from the list of the nine criteria and requires
only four of the remaining seven symptoms for diagnosis,
could increase the specificity of the diagnosis [6]. Never-
theless there are still no data confirming the validity of
these models.
It is to note that, as Bailey suggested [17], culture may
influence symptom expression, as an example individuals
of the Asian culture suffering from depression tend to
present somatic symptoms of depression neglecting the
psychological symptoms.
Nevertheless the issue of Adjustment Disorder remains
unresolved. This issue needs more attention, because
there are still many clinicians that erroneously consider
Adjustment Disorder always as a normal transition. The
real problem is that cancer related stressors persist for long
time, so that diagnosis should be modified and, treat-
ments are delivered with further delay.
Recently several multiphasic screening studies to detect
depression have shown an increase in sensitivity and spe-
cificity of the diagnosis [5,24,25].
Another issue in detecting depressive disorders among
cancer patients is the methodology of the interview. WhileClinical Practice and Epidemiology in Mental Health 2007, 3:2 http://www.cpementalhealth.com/content/3/1/2
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administering rating scales in a waiting room or interview-
ing patients over the telephone offer practical advantages
such as simplicity, low cost, and applicability to large
samples, there is no doubt that a comprehensive psychiat-
ric assessment is warranted to diagnose a Major Depres-
sive Disorder, and this is difficult without seeing the
patient. Moreover, patients need time and space. Most
important data are often obtained in the last minutes of
an hour visit in a dedicated room. And this has to do with
relationship, not with methodology.
3. Features of depression
To better understand the complex nature of depression in
cancer patients, it is useful to consider several aspects. A
fundamental issue is that depressive disorders are syn-
dromes not diseases, and include a variety of mood distur-
bances and clinical presentations. Negative mood along
with low energy, poor concentration, loss of interests,
memory disturbances, low self-esteem, guilt feelings,
hypochondriac preoccupation, sleep and appetite distur-
bances and hopelessness are the most common symp-
toms of Major Depressive Disorder. Features
underrepresented in endogenous depression, such as psy-
chic and somatic anxiety, somatic complaints are more
common in atypical depression. However, a wide variety
of clinical pictures can actually be observed in depressed
patients. As an example, current psychiatric classification
systems tend to underestimate the role played in
depressed patients by symptoms such as anger, irritability,
and hostility [26,27].
As an alternative model in the assessment of depressive
disorders many authors promoted a clinimetric approach
rather than the psychometric model; this because in clini-
cal practice, psychiatrists may weigh factors such as the
progression of disease, the overall severity of the disorder,
the patients' social support and their adaptation and resil-
ience and reaction to stressful life circumstances [28,29].
Physicians may find this model useful and practical in the
assessment of depressive symptoms among cancer
patients. Coping strategies, feelings of loss, cognitive
adaptation and transition are all fundamental psycholog-
ical aspects that affect different clinical manifestations of
every single cancer patient [30]. These components vary
tremendously whether you are assessing a female with
breast cancer diagnosed and treated ten years ago, or if
you are dealing with a female with colon cancer, recently
stomized.
Another question has to do with fatigue, the most fre-
quently reported side effect of cancer treatment, with a
prevalence ranging from 25% to 99%[31]. However,
fatigue is also a feeling state not related to cancer treat-
ments. Even though fatigue may be associated with
depression in patients treated with chemotherapy, too
often is taken for depression [32,33]. Moreover, in a ran-
domized double/blind trial Morrow demonstrates that
paroxetine affects depressive symptoms but not fatigue
[34]. In fact, fatigue due to chemotherapy does not
include an emotional component while fatigue related to
a depressive syndrome does, obviously an individual in
chemotherapy experiencing fatigue can develop feelings
of demoralization. Bower found that in breast cancer
patients not in chemotherapy, fatigue was associated with
flatter cortisol slope, what may reflect a HPA axis altera-
tions. [35]. To develop cancer is a very traumatic experi-
ence for patients, facing the possibility of death, changes
in the body image, fear of invasive treatments and pain,
changes in their role in the family, in their work environ-
ment and in the society at large, all representing sources of
acute stress. Stress is defined by stimuli (stressors), subjec-
tive reports of an experience, a general non-specific
increase in arousal, and the feedback to the brain from
this response.
Fortunately many types of cancer are becoming chronic
conditions. But unfortunately humans, like other ani-
mals, are not prepared to deal with prolonged stressors.
Those familiar with these patients know how their organ-
izers are full of follow-up visits and check-ups for a long
time. Talking with them you can learn how these individ-
uals view their time. It is difficult to generalize depression
in such context. In this prospective we could consider
some manifestation of psychological suffering as a psy-
choneuroendocrinal alteration. In addition, the behav-
ioural alterations that develop during illness are not just
the result of a decreased ability to react to the external
world and engage in physical activities. Pro-inflammatory
cytokines produced by peripheral immune cells could
function as a motivational signal that tells the brain to
change the organism priorities in face of the threat repre-
sented by danger signals. This reorganization of priorities
results in changes at the subjective, behavioural and phys-
iological levels [36].
4. Biological correlates
There have been several studies of psychoneuroimmuno-
logical mechanisms and cancer. Biological alterations
were investigated in relation to coping styles, psychologi-
cal status, social support and survival. Most of these stud-
ies were conducted among patients affected by breast
cancer, given that for this disease survival at five years is
88% [37].
Increasing evidence has suggested that circadian patterns
of cortisol secretion are altered in cancer patients with
advanced disease [38-40]. Abercombie and colleagues
showed that women with metastatic breast cancer had sig-
nificantly flatter diurnal cortisol rhythms as compared
with healthy controls [41]. Sephton found that flattenedClinical Practice and Epidemiology in Mental Health 2007, 3:2 http://www.cpementalhealth.com/content/3/1/2
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diurnal cortisol slopes were associated with decreased sur-
vival time among women with metastatic breast cancer
[42], while Osborne's study found no evidence that corti-
sol and prolactin levels were associated with immune or
psychosocial variables in breast cancer patients [43], sim-
ilar results were obtained in a largest controlled study
[44].
An important finding is that cortisol level in metastatic
breast cancer is related to the quality of social support,
belonging, appraisal, and tangible support [45].
Only one randomized controlled study showed that levels
of omega-3 fatty acid are associated with minor (but not
major) depression in lung cancer patients, unfortunately
psychiatric diagnosis was made using HADS [46].
There are still inconsistent data regarding the association
between mood disorders, NK cells, cytokines, cancer
development and survival [47-50]. In 116 breast cancer
patients exposure to stress was associated with lower NK
cell lysis and diminished responsiveness of NK to rIFN-γ
[51]; while among men affected by prostate cancer opti-
mism and less anger suppression was associated with
greater natural killer cell cytotoxicity [52]. Consistently a
structured group therapy in patients affected by malignant
melanoma reduced distress and showed increases in NK
cell cytotoxic activity as compared to controls [53]. Mus-
selman first, reported that higher than normal plasma Il-
6 levels were associated with a diagnosis of major depres-
sion in a small sample of cancer patients [54]. This finding
was confirmed in a larger sample by Jehn et al., therefore
the authors proposed the IL-6 increased plasma concen-
tration as a biomarker of depression among cancer
patients [55].
Costanzo et al. found that among 61 patients with
advanced ovarian cancer social support play a protective
role with respect to IL-6 elevations, and IL-6 may be an
independent marker of health-related quality of life [56].
Raison and Miller reviewed the role of cytokines in cancer
patients and suggested that inflammation provides a
physiologic substrate that promotes mood disorders [57].
In spite of the increasing evidence that IL-6 and other pro-
inflammatory cytokines may play a role in the pathophys-
iology of mood disorders and cause behavioural and neu-
roendocrine consequences, in cancer patients these
phenomena are rather more complicated. In fact, different
data regarding the relation between IL-6 and cancer are
known. Consistent results have been shown that IL-6 is a
pleiotropic regulator of prostate cancer cell growth, and
serum IL-6 levels has prognostic significance in patients
with metastatic prostate cancer [58,59]. Moreover IL/6
induced basic fibroblast growth factor dependent angio-
genesis in basal cell carcinoma [60]. In addition IL-6 may
be involved in tumor-host interactions potentially favour-
ing uveal melanoma growth, survival and proliferation
[61]. Recently Berger reported that the gene encoding the
IL6 is a susceptibility factor affecting racial and ethnic dif-
ferences in breast cancer survival. [62]. All these data sug-
gest that the general assertion regarding IL-6, depression
and cancer needs great caution. Besides, it is well known
that proinflammatory cytokines may cause depression or
sickness behaviour and that psychiatric interventions
affect levels of pro-inflammatory cytokines. A randomized
study on the efficacy of Cognitive-Behavioral Therapy in
insomnia secondary to breast cancer provides evidence
that treating insomnia can alter cytokine production [63].
In summary, apathy, social isolation, sleep disturbance,
fatigue, anorexia, weight loss, cognitive disturbance,
decreased libido and psychomotor retardation are symp-
toms of both Major Depression and cytokine-induced
sickness syndrome, whereas guilt, depressed mood and
suicidal ideation are more common in Major Depressive
Disorder.
Neuroimaging correlates are emerging. Matsuoka demon-
strated that cancer survivors with intrusive recollections
had a significantly smaller total amygdala volume as com-
pared with the total amygdala volume in cancer survivors
without intrusive recollections [64]. In a case control
study, Yoshikawa reported an alteration in amygdala vol-
ume associated with depressed mood after cancer diagno-
sis in 51 cancer survivors. [65]. Data obtained using PET
in depressed cancer patients showed cerebral functional
alterations similar to those founded among primary
depressed patients [66,67].
5. Depression as a risk factor in the prognosis of 
cancer
Data regarding the influence of psychological factors on
the prognosis of cancer are available. Psychological status
seems to predict the length of survival in several types of
cancer such as melanoma, non-small-cell lung cancer,
breast and kidney cancer. Longer follow-up indicate that a
high fighting spirit confers no survival advantage, while in
patients who were disease-free at 5 years, their baseline
helpless/hopeless response still exerted a significant effect
on disease-free survival beyond 5 (and up to 10) years.
The effect is therefore maintained for up to 10 years of fol-
low-up [68]. These results were usually obtained by vali-
dated instruments like the General Health
Questionnaires, the Quality of Life Index or the Mental
Adjustment to Cancer.
However there are few data regarding the unique role of
mood in predicting survival. Results from 8-year follow-
up study among 10.000 patients demonstrated that theClinical Practice and Epidemiology in Mental Health 2007, 3:2 http://www.cpementalhealth.com/content/3/1/2
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coexistence of cancer and depression is associated with an
increased risk of death [69].
Prieto, in the largest oncologic study that used standard-
ized psychiatric criteria, found that among 199 hemato-
logic cancer patients after stem-cell transplantation, Major
Depressive Disorder predicted higher 1- and 3-year case-
fatality-rate, and there was a trend for patients with minor
depression to survive longer than patients with no depres-
sion [6]. Faller reported that in lung cancer patients emo-
tional distress and depressive coping style predict short
survival [70]. Recent studies found that high scores on a
"minimizing the illness" scale predict longer survival
[71,72]. Although "minimizing the illness" coping style
may have clinical utility, so far this construct has not been
studied in relation to mood disorders. The impact of
depression on mortality has not been definitively shown.
Spiegel and Giese-Davis reviewed the link between
depression and cancer progression, and suggested that
there is not strong evidence supporting a link of depres-
sion with cancer incidence, though some methodological
problems may have affected such results [73]. However
untreated depressive disorders may be linked to faster pro-
gression.
The interpretation of these results is not univocal: depres-
sion may have a direct neuroimmune effect, or depressed
patients may show poorer adherence to cancer treatment,
or depression related behaviours affect several aspects of
patients life such as health status, quality of life, parental
role, working role. Results as those obtained by Fawzy on
malignant melanoma in a 10-year follow-up study, sug-
gest that a brief structured psychoeducational group inter-
vention can moderately affect survival. [74].
Nevertheless, examining the effect on survival of psycho-
therapy, Palmer and Coyne correctly noticed that studies
in which survival was not designated as a primary out-
come cannot be given the same weight as studies designed
with survival as an a priori end point [75].
6. Treatment
The single most important factor precluding treatment
among depressed cancer patients is the misconception
that for such patients being depressed is normal. Moreo-
ver most oncologists are unfamiliar with depressive disor-
ders. Emerging data confute the notion that depression is
inevitable and untreatable [76]. Therapeutic nihilism is
not justified anymore. The evidence-based health care
(screening and selective treatment) currently delivered to
depressed cancer patients in selected oncology centres
should be widespread. A range of options for service
development should be outlined, rather than just one pre-
ferred method of service delivery. The training needs of
staff must be fitted into the service model, as opposed to
their training experience dictating the shape of the service,
as it has happened in the past [77]. Unfortunately few
data from clinical trials are available on the effectiveness
of treatment for depression among cancer patients [78].
6.1 Pharmacological treatment
Fisch provided a brilliant review of the treatment of
Depressive Disorders among cancer patients, in which he
focused on the inadequate quality of research in this field
[79]. At present there are only 10 randomized trials com-
paring antidepressants to placebo. An explanation, sug-
gested by Fisch, is the relative aversion of patients and
family members to the placebo controlled study design.
One could argue that the lack of Randomized Controlled
Trials is the cause of under treatment of such disorders.
There are also doubts about the physicians rigorous clini-
cal evidence based prescriptions. Furthermore, as shown
by Ashbury in lung cancer patients there is a weak correla-
tion between detection of depressive disorders and treat-
ment [16].
Another important issue is that of the heterogeneity of the
outcomes, reflecting the same problems of assessment,
and therefore data are difficult to compare. It should also
be noted that there are several open or uncontrolled stud-
ies suggesting potentially improvements in depressed can-
cer patients. Probably, thank to the clinical experience
with new antidepressants effectiveness, in the near future
we could have more RCT data. In addition antidepressants
have potential usefulness for the management of symp-
toms and conditions other than depression, such as hot
flashes and pain [80-83], so they are often prescribed to
cancer patients [84,85].
However, prescribing antidepressants to cancer patients
requires specific knowledge, experience and caution. One
must take into account: the anticholinergic side effects of
tricyclic antidepressants, the pro-emetic effect of SSRIs
and their potential effects on the pharmacokinetics of
other drugs, and the specific syndromes occurring in com-
bination with chemotherapy [86]. Medication should be
tailored to each cancer patient based on the different char-
acteristics of the various drugs [87-89]. We do not agree
with the recommendations that oncologists should pre-
scribe antidepressant treatments, as other authors sug-
gested. These decisions should be the responsibility of the
consulting psychiatrist, because of his/her specific knowl-
edge. Simply adding an antidepressant to other medica-
tions differs notably from a psychiatric prescription. One
implication occurs with sleep disturbances, that often
mirror a depressive disorder, while patients receive unsuit-
able medication such as benzodiazepines. Moreover, the
patient's perception of being part of an active treatment isClinical Practice and Epidemiology in Mental Health 2007, 3:2 http://www.cpementalhealth.com/content/3/1/2
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by far different from passively waiting for the medication
effect.
6.2 Psychological treatment
Efficacy of psychological interventions in cancer
depressed patients has been demonstrated, but effective-
ness study are still lacking [90]. A systematic review of psy-
chological interventions among cancer patients identified
129 trials that involved psychosocial outcomes [91]; only
24 studies showed an advantage for the intervention in
terms of the endpoint of depression [79]. Previous reviews
were more enthusiastic about the benefits of psychologi-
cal interventions, but their approach was less conserva-
tive, particularly regarding the outcome measures for
depression [92,93]. It is difficult to compare the effective-
ness of psychotherapeutic interventions when the studies
include several different techniques, procedures are not
clearly spelled-out, or outcomes are different. Newell and
colleagues proposed ten recommendations to improve
the reporting of future randomized controlled trials of
psychological therapies [91]. At present most interven-
tions are cognitive behavioural oriented. Some authors
recommend a cognitive approach to the treatment of
depression among cancer patients, others reported that
group therapy is more effective, although these indica-
tions should take into consideration the clinical variables
of every single situation. It is known that in psychotherapy
research there are several methodological difficulties, and
this is even more true among cancer patients. Elements of
fundamental relevance of the interventions are: brief
structure and a clear intervention targeting. Despite these
scientific issues, the main problem is that too often pro-
viders of psychological therapies are not adequately
trained in psycho-oncology, or they have an inadequate
contact with the oncology staff. It is important to notice
that data regarding the effect of psychological interven-
tions on biological parameters are available in the field of
psycho-oncology more than in other fields.
7. Unmet needs of the cancer depressed patients
In oncology settings it is emerging the notion that cancer
patients should not tolerate their depressive symptoms
and the importance of appropriately informing them
about it. Unfortunately many issues are still unresolved.
The report from the Expert Working Group of the Euro-
pean association for Palliative Care has stressed the major
unresolved problems regarding depression and cancer
[90]. Among the several recommendations provided,
there are the following ones: the need for specialized men-
tal health professionals, and their different roles depend-
ing on local circumstances; the need of a close
relationship between the oncology staff and the consulta-
tion-liaison psychiatry; the concept that antidepressants
should be utilized without delay once the diagnosis of
Major Depression has been established. It has also been
suggested that staff training in detecting Depressive Disor-
ders may not be a sufficient condition for a better manage-
ment of depressive disorders. Besides, Passik and
colleagues demonstrated that rarely oncologists recognize
symptoms of depression, and depressed patients referred
to a psychiatrist or a psychologist represent still a little per-
centage of total [94]. In addition, often differences in cul-
tural perceptions of disease are underestimated.
Psychological differences by background can make a
major difference in the response of individuals to disease
[17]. Also compliance varies for patients in the U.S.,
North Europe, or other countries, such as Italy.
As reported by Ell [8], in her study among the low-
income, ethnic minority, only 12% of all the women
affected by Major Depression were receiving medications,
while among 10% of the middle-to upper income white
women who met diagnostic criteria for major depression
80% were receiving antidepressants [7]. However the Mul-
tifaceted Oncology Depression Program Intervention,
organized by Dwight-Johnson and colleagues, showed
that depressive disorders can be successfully treated in a
public sector oncology setting serving low-income
patients. This model shows the importance of collabora-
tion between several roles at different levels: community
representatives, administrative and clinical committees
[76].
Another underrated aspect is that not all patients want to
have their depression recognised and treated [5,79]. Vari-
ous factors can explain this phenomenon, culture,
patient's personality, prior experience with cancer, coping
styles, gender differences. Fisch reported "that patients
and their families know that a positive attitude or a "fight-
ing spirit" is important to either the health outcome or the
clinician willingness to treat the cancer aggressively, and
this kind of belief can translate into a perceived risk in dis-
closing depressive symptoms" [79] This attitude could be
related to the on-line information, more and more availa-
ble without an adequate filter.
Recently it has been suggested that spirituality and spirit-
ual coping are important to women with gynaecological
cancer and that staff members should consider these
issues [95]. Another important unmet need is the lack of
links between psychiatric services and pain clinics; unfor-
tunately, in many general hospitals, mental health teams
have scarce resources and skill for managing patients with
chronic pain. In addition it is well known that patients
with depressive disorders have higher costs of general
medical-care services compared with their non depressed
peers. Treatment of depression may reduce these costs, in
many ways including reduction of sickness-absence.Clinical Practice and Epidemiology in Mental Health 2007, 3:2 http://www.cpementalhealth.com/content/3/1/2
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Institutions may provide new training programs as psychi-
atric subspecialties. Only in 2003 the American Board of
Psychiatry and Neurology, trough the American Board of
Medical Specialties, approved Psychosomatic Medicine as
a psychiatric subspecialty. This could be due to the fact
that in recent decades many diseases, including cancer,
became chronic conditions, requiring more complex
health care delivery.
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